<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25712020</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>07</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1420-9071</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>72</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2015</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cellular and molecular life sciences : CMLS</Title>
          <ISOAbbreviation>Cell Mol Life Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Targeting PI3K/AKT/mTOR network for treatment of leukemia.</ArticleTitle>
        <Pagination>
          <StartPage>2337</StartPage>
          <EndPage>2347</EndPage>
          <MedlinePgn>2337-47</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00018-015-1867-5</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Increased activity of PI3K/AKT/mTOR pathway has been observed in a huge number of malignancies. This pathway can function as a prosurvival factor in leukemia stem cells and early committed leukemic precursors and its inhibition is regarded as a therapeutic approach. Accordingly, the aim of this review is to evaluate the PI3K/Akt/mTOR inhibitors used in leukemia models.</AbstractText>
          <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Inhibition of the PI3K/AKT/mTOR pathway has been reported to have beneficial therapeutic effects in leukemias, both in vitro in leukemia cell lines and in vivo in animal models. Overall, the use of dual PI3K/mTOR inhibitor, dual Akt/RTK inhibitor, Akt inhibitor, selective inhibitor of PI3K, mTOR inhibitor and dual PI3K/PDK1 inhibitor in CML, AML, APL, CLL, B-ALL and T-ALL has a better therapeutic effect than conventional treatments.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Targeting the PI3K/Akt/mTOR pathway may have pro-apoptotic and antiproliferative effects on hematological malignancies. Furthermore, modulation of miRNA can be used as a novel therapeutic approach to regulate the PI3K/Akt/mTOR pathway. However, both aspects require further clinical studies.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bertacchini</LastName>
            <ForeName>Jessika</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Medicine, Dentistry and Morphology, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Heidari</LastName>
            <ForeName>Nazanin</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mediani</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Capitani</LastName>
            <ForeName>Silvano</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shahjahani</LastName>
            <ForeName>Mohammad</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ahmadzadeh</LastName>
            <ForeName>Ahmad</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saki</LastName>
            <ForeName>Najmaldin</ForeName>
            <Initials>N</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>02</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Cell Mol Life Sci</MedlineTA>
        <NlmUniqueID>9705402</NlmUniqueID>
        <ISSNLinking>1420-682X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007938" MajorTopicYN="N">Leukemia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081082" MajorTopicYN="Y">Phosphoinositide-3 Kinase Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2014</Year>
          <Month>11</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>2</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2015</Year>
          <Month>2</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>8</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25712020</ArticleId>
        <ArticleId IdType="doi">10.1007/s00018-015-1867-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Cancer Metastasis Rev. 2009 Dec;28(3-4):305-16</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20013032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell Signal. 2012 Feb;24(2):363-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21978953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood. 2008 Mar 15;111(6):3183-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18187662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Rev Mol Cell Biol. 2010 May;11(5):329-41</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20379207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Exp Hematol. 2013 Sep;41(9):799-807.e4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23660068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Rev Cancer. 2010 Jan;10(1):37-50</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19956173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2010 Nov 15;16(22):5424-35</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20884625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leukemia. 2012 Jun;26(6):1195-202</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22143671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leukemia. 2010 Jan;24(1):13-21</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19865108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leukemia. 2007 Sep;21(9):1921-30</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17581609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Biol Ther. 2014 Feb;15(2):207-15</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24100660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leuk Res. 2012 Apr;36(4):509-13</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22285507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curr Med Chem Anticancer Agents. 2005 Nov;5(6):575-89</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16305480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Front Oncol. 2014 May 16;4:108</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24904824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mol Cancer Ther. 2006 Nov;5(11):2815-23</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17121928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leukemia. 2012 May;26(5):927-33</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22094587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PLoS One. 2010 Jan 14;5(1):e8719</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20090934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stem Cells. 2014 Sep;32(9):2324-37</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24806995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leukemia. 2007 May;21(5):886-96</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17361225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncol Rep. 2014 Jul;32(1):293-301</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24842472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncologist. 2001;6 Suppl 2:1-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11331433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet. 2008 Mar 22;371(9617):1030-43</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18358930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Natl Cancer Inst. 2011 Apr 6;103(7):553-61</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21422402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PLoS One. 2013;8(1):e53518</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23320091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Int J Mol Sci. 2013 Feb 13;14(2):3874-900</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23434669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>BMC Cancer. 2013 Sep 27;13:440</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24073922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2013 Oct 10;369(15):1472</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24106948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood. 2012 Sep 27;120(13):2679-89</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22826565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Science. 2013 Jul 26;341(6144):1236566</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23888043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hematology. 2014 Apr;19(3):141-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23796062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood. 2007 Aug 1;110(3):1025-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17426258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Rev Drug Discov. 2009 Aug;8(8):627-44</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19644473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Annu Rev Pathol. 2014;9:287-314</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24079833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nature. 2005 Jun 9;435(7043):834-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15944708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mol Cancer Res. 2007 Jan;5(1):95-108</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17259349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Treat Rev. 2004 Feb;30(1):37-51</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14766125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haematologica. 2010 Mar;95(3):415-23</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20007139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood. 2009 Jul 16;114(3):647-50</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19458356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leukemia. 2014 Nov;28(11):2197-205</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24699302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Food Chem Toxicol. 2013 Dec;62:246-54</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23994707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell Cycle. 2008 Apr 15;7(8):965-70</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18414037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Cancer Res Clin Oncol. 2008 Aug;134(8):861-72</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18288489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crit Rev Oncol Hematol. 2004 Jun;50(3):197-222</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15182826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncotarget. 2012 Aug;3(8):811-23</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22885370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tumour Biol. 2014 Nov;35(11):10627-33</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25234716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PLoS One. 2013 Aug 23;8(8):e74420</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24009772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phytother Res. 2014 Mar;28(3):458-64</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23813779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>FEBS Lett. 2011 Jan 21;585(2):402-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21187093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell Death Differ. 2014 Jan;21(1):100-12</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24076586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2011 Jan 15;17(2):212-21</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21098337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haematologica. 2010 Jan;95(1):110-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19713228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leuk Res. 2012 Mar;36(3):342-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22137317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood. 2003 Aug 1;102(3):972-80</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12702506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Biol Chem. 2013 Aug 2;288(31):22836-48</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23788636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood. 2008 Jan 15;111(2):846-55</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17928528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood. 2005 Dec 15;106(13):4261-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16150937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood. 2011 Dec 8;118(24):6399-402</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22021366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2011 Jul 1;17(13):4378-88</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21415215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PLoS One. 2014 Mar 06;9(3):e88298</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24603487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood. 2010 May 20;115(20):4030-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20354168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell. 2013 May 23;153(5):1050-63</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23706742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncotarget. 2014 Oct 30;5(20):10034-47</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25296981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncol Rep. 2014 May;31(5):2245-51</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24676995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood. 2008 Jan 1;111(1):379-82</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17878402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Genet. 2011 Apr;204(4):171-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21536234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Lett. 2013 Aug 9;336(1):114-26</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23612073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood. 2013 Jan 17;121(3):499-509</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23223432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood. 2010 Sep 23;116(12):2078-88</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20522708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood. 2010 Nov 18;116(20):4262-73</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20668229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell Death Dis. 2013 Oct 03;4:e827</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24091670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell. 2007 Jun 29;129(7):1261-74</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17604717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leukemia. 2013 Mar;27(3):586-94</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23090679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curr Cancer Drug Targets. 2011 Jan;11(1):56-71</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21062243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Res. 2010 Oct 15;70(20):8097-107</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20876803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leukemia. 2003 Mar;17(3):590-603</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12646949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood. 2014 May 29;123(22):3390-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24615777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Med. 2003 Sep;9(9):1158-65</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12897778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncotarget. 2012 Apr;3(4):371-94</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22564882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Med Oncol. 2014 Nov;31(11):266</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25287907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell Cycle. 2011 Apr 1;10(7):1050-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21389767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Cell Biol. 2002 Sep;4(9):648-57</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12172553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood. 2010 Oct 21;116(16):3023-32</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20664053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2006 Jun 15;354(24):2542-51</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16775235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Br J Haematol. 2014 Jan;164(1):146-50</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24111951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leukemia. 2013 Mar;27(3):650-60</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23038273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PLoS One. 2011;6(11):e27008</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22073238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 2003 Nov 15;21(22):4256-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14615464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PLoS One. 2013;8(2):e56473</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23437141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Br J Haematol. 2013 Jul;162(2):285-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23594092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood Cancer J. 2013 Sep 20;3:e149</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24056719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Int J Biochem Cell Biol. 2005 Jun;37(6):1168-72</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15778081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood Cancer J. 2014 Jul 11;4:e228</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25014775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood. 2006 Feb 1;107(3):1149-55</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16195324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leukemia. 2014 Apr;28(4):739-48</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23892718</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
